Skip to content
Open menu

Hodgkin lymphoma

Hodgkin lymphoma is a cancer of the lymphatic tissue. Usually, it starts in a lymph node and the first detected sign is an enlarged lymph node.

Hodgkin lymphoma is most typically diagnosed in young adults. Today, its prognosis is good. Hodgkin lymphoma is classified into subcategories (classic and lymphocyte-predominant) by stage.

Risk of disease

The exact cause of Hodgkin lymphoma is not known. It is found more frequently than average in people with a disease that leads to immunodeficiency (such as AIDS) and people who are using medication that causes immunodeficiency (such as organ transplant medication). Epstein-Barr infection (mononucleosis) has been found to be a risk factor.

Symptoms

The only initial sign of Hodgkin lymphoma may be a swollen lymph node in the neck. Most patients are symptom-free at the time of diagnosis. The symptoms partly depend on the location of the tumor. A painless cough may be associated with the disease if mediastinal lymph nodes are enlarged. Some patients experience general symptoms, so-called ‘B’ symptoms, such as fever, sweating and tiredness.

Diagnosis

The disease is diagnosed by examining a piece of tissue, usually obtained by removing a swollen lymph node. Once the diagnosis is established, the cancer is staged. Usually, this involves a CT scan of the body and an FDG-PET/CT scan. A bone marrow biopsy may also be performed to ensure successful staging.

Treatment

The choice of treatment depends on the stage of disease and the symptoms. The most common treatments include chemotherapy and radiotherapy and combinations thereof. If the disease recurs, biological targeted agents may be used, and stem cell transplantation may be included in the treatment.

 

Read more

Chief Clinical Director of Docrates Cancer Center: “Genetic information is an essential part of modern cancer care”

New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...

Read more

Customer message 3. September, 2024

With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...

The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center

On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....

Breast reconstruction aims for a great quality of life — the new breast is usually made from the patient’s own tissue

Breast cancer is a serious disease that requires individual care and expertise. As part of cancer treatment, the patient may...

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00